uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.954 | Q16 | What Small molecule therapies have been approved by the FDA to treat congenital hypothyroidism? | Levothyroxine Sodium is the only Small molecule therapy approved by the FDA to treat congenital hypothyroidism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "congenital hypothyroidism" OR LOWER(mesh_heading) = "congenital hypothyroidism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924802', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924809', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924816', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924823', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924830', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924837', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924844', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924851', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924858', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924865', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924872', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924879', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924886', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924893', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924900', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924907', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924914', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924921', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924928', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924935', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924942', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924949', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924956', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924963', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924970', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924977', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924984', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924991', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_924998', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925005', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925012', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925019', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925026', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925033', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925040', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925047', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925054', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925061', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925068', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925075', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925082', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925089', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925096', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925103', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925110', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925117', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925124', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925131', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925138', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925145', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925152', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925159', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925166', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925173', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925180', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925187', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925194', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925201', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925208', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925215', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925222', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925229', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925236', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925243', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925250', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925257', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925264', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925271', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925278', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925285', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925292', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925299', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925306', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925313', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925320', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925327', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925334', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925341', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925348', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925355', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925362', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925369', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925376', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925383', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925390', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925397', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925404', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925411', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925418', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925425', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925432', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925439', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925446', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925453', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925460', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925467', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925474', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925481', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925488', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}, {'UUID': 'DrugTargetsIndication121923_text_925495', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000126351', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.362 | Q16 | What Small molecule therapies have been approved by the FDA to treat Beta-thalassemia? | There are no drug Small molecule therapies approved to treat Beta-thalassemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "beta-thalassemia" OR LOWER(mesh_heading) = "beta-thalassemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.982 | Q16 | What Small molecule therapies have been approved by the FDA to treat dermatomyositis? | Prednisone is the only Small molecule therapy approved by the FDA to treat dermatomyositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dermatomyositis" OR LOWER(mesh_heading) = "dermatomyositis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217629', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_217630', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_217837', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_217838', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218045', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218046', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218253', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218254', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218461', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218462', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218669', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218670', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218877', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_218878', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219085', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219086', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219293', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219294', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219501', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219502', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219709', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219710', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219917', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_219918', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220125', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220126', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220333', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220334', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220541', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220542', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220749', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'dermatomyositis'}, {'UUID': 'DrugTargetsIndication121923_text_220750', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.523 | Q16 | What Small molecule therapies have been approved by the FDA to treat Kaposi's sarcoma? | There are no drug Small molecule therapies approved to treat Kaposi's sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "kaposi's sarcoma" OR LOWER(mesh_heading) = "kaposi's sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1261 | Q16 | What Small molecule therapies have been approved by the FDA to treat lung cancer? | There are 2 Small molecule therapy drugs that are approved to treat lung cancer which are as follows: Trametinib Dimethyl Sulfoxide and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lung cancer" OR LOWER(mesh_heading) = "lung cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927732', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927739', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927746', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927753', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927760', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927767', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927774', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927781', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927788', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927795', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927802', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927809', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927816', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927823', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927830', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927837', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927844', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927851', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927858', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927865', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927872', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927879', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927886', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927893', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927900', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927907', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927914', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927921', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927928', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927935', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927942', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927949', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927956', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927963', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927970', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927977', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927984', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927991', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_927998', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928005', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928012', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928019', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928026', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928033', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928040', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928047', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928054', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928061', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928068', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928075', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928082', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928089', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928096', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928103', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928110', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928117', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928124', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928131', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928138', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928145', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928152', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928159', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928166', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928173', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928180', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928187', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928194', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928201', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928208', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928215', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928222', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928229', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928236', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928243', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928250', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928257', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928264', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928271', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928278', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928285', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928292', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928299', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928306', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928313', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928320', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928327', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928334', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928341', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928348', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928355', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928362', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928369', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928376', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928383', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928390', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928397', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928404', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928411', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928418', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}, {'UUID': 'DrugTargetsIndication121923_text_928425', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1070 | Q16 | What Small molecule therapies have been approved by the FDA to treat fibroma? | There are no drug Small molecule therapies approved to treat fibroma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fibroma" OR LOWER(mesh_heading) = "fibroma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1038 | Q16 | What Small molecule therapies have been approved by the FDA to treat erythema multiforme? | There are 2 Small molecule therapy drugs that are approved to treat erythema multiforme which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "erythema multiforme" OR LOWER(mesh_heading) = "erythema multiforme") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217665', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_217873', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_218081', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_218289', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_218497', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_218705', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_218913', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_219121', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_219329', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_219537', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_219745', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_219953', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_220161', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_220369', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_220577', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_220785', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_226361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_226646', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_226931', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_227216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_227501', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_227786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_228071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_228356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_228641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_228926', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_229211', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_229496', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_229781', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_230066', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_230351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_230636', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_230921', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_231206', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_231491', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_231776', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_232061', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}, {'UUID': 'DrugTargetsIndication121923_text_232346', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.855 | Q16 | What Small molecule therapies have been approved by the FDA to treat bulimia nervosa? | There are no drug Small molecule therapies approved to treat bulimia nervosa. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bulimia nervosa" OR LOWER(mesh_heading) = "bulimia nervosa") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.183 | Q16 | What Protein therapies have been approved by the FDA to treat inflammation? | Cyclosporine is the only Protein therapy approved by the FDA to treat inflammation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "inflammation" OR LOWER(mesh_heading) = "inflammation") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100644', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1100771', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1100898', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101025', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101152', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101279', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101406', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101533', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101660', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101787', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1101914', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102041', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102168', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102295', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102422', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102549', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102676', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102803', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1102930', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}, {'UUID': 'DrugTargetsIndication121923_text_1103057', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1198 | Q16 | What Small molecule therapies have been approved by the FDA to treat injury? | Triamcinolone Acetonide is the only Small molecule therapy approved by the FDA to treat injury. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "injury" OR LOWER(mesh_heading) = "injury") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221873', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_221938', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_222003', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_222068', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_222133', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_222198', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_222263', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}, {'UUID': 'DrugTargetsIndication121923_text_222328', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1360 | Q16 | What Small molecule therapies have been approved by the FDA to treat narcolepsy-cataplexy syndrome? | There are 6 Small molecule therapy drugs that are approved to treat narcolepsy-cataplexy syndrome which are as follows: Dextroamphetamine, Methylphenidate, Amphetamine Sulfate, Pitolisant Hydrochloride, Armodafinil, and Sodium Oxybate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "narcolepsy-cataplexy syndrome" OR LOWER(mesh_heading) = "narcolepsy-cataplexy syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418362', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418375', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418388', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418401', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418414', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418427', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418440', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418453', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418466', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418479', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418492', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418505', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418518', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418531', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418544', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418557', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418570', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418583', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418596', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418609', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418622', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418635', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418648', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418661', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418674', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418687', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418700', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418713', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418726', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418739', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418752', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418765', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418778', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418791', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418804', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418817', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418830', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418843', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418856', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418869', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418882', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418895', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418908', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418921', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418934', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418947', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418960', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418973', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418986', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_418999', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419012', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419025', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419038', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419051', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419064', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419077', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419090', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419103', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419116', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_419129', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'drugType': 'Small molecule', 'actionType': 'releasing agent', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439211', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439242', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439273', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439304', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439335', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439366', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439397', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439428', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439459', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439490', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439521', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439552', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439583', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439614', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439645', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439676', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439707', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439738', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439769', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439800', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439831', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439862', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439893', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439924', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439955', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_439986', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440017', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440048', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440079', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440110', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440141', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440172', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440203', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440234', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440265', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440296', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440327', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440358', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440389', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_440420', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142319', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.111 | Q16 | What Protein therapies have been approved by the FDA to treat breast ductal carcinoma in situ? | There are no drug Protein therapies approved to treat breast ductal carcinoma in situ. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breast ductal carcinoma in situ" OR LOWER(mesh_heading) = "breast ductal carcinoma in situ") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1620 | Q16 | What Small molecule therapies have been approved by the FDA to treat sex cord-gonadal stromal tumor? | There are no drug Small molecule therapies approved to treat sex cord-gonadal stromal tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sex cord-gonadal stromal tumor" OR LOWER(mesh_heading) = "sex cord-gonadal stromal tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1084 | Q16 | What Small molecule therapies have been approved by the FDA to treat freckles? | There are 2 Small molecule therapy drugs that are approved to treat freckles which are as follows: Fluocinolone Acetonide and Tretinoin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "freckles" OR LOWER(mesh_heading) = "freckles") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242236', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_242252', 'drugName': 'Fluocinolone Acetonide', 'tradeNames_list': "['Capex', 'Derma-smoothe/fs', 'Dermotic', 'Fluocet', 'Fluocinolone acetonideFluonid', 'Fluotrex', 'Fs shampoo', 'Iluvien', 'Retisert', 'SynalarSynalar fte', 'Synalar-c', 'Synalar-hp', 'Synalar-n', 'Synandone', 'Yutiq']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1963, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_1053520', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_1053561', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_1053602', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_1053643', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_1053684', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}, {'UUID': 'DrugTargetsIndication121923_text_1053725', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanosis', 'efo_term': 'freckles'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.43 | Q16 | What Protein therapies have been approved by the FDA to treat HIV infection? | There are no drug Protein therapies approved to treat HIV infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hiv infection" OR LOWER(mesh_heading) = "hiv infection") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.752 | Q16 | What Small molecule therapies have been approved by the FDA to treat amyotrophic lateral sclerosis? | Riluzole is the only Small molecule therapy approved by the FDA to treat amyotrophic lateral sclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "amyotrophic lateral sclerosis" OR LOWER(mesh_heading) = "amyotrophic lateral sclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_636224', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636247', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636270', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636293', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636316', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636339', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636362', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636385', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636408', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636431', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636454', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636477', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636500', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636523', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636546', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636569', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636592', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636615', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636638', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636661', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636684', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636707', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636730', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636753', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636776', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636799', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636822', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636845', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636868', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_636891', 'drugName': 'Riluzole', 'tradeNames_list': "['Exservan', 'Rilutek', 'Riluzole', 'Teglutik', 'Tiglutik kit']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.126 | Q16 | What Protein therapies have been approved by the FDA to treat chronic kidney disease? | There are 2 Protein therapy drugs that are approved to treat chronic kidney disease which are as follows: Difelikefalin and Velcalcetide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic kidney disease" OR LOWER(mesh_heading) = "chronic kidney disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092253', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092257', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092261', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092265', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092269', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092273', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092277', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092281', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092285', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092289', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092293', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1092297', 'drugName': 'Difelikefalin', 'tradeNames_list': "['Korsuva']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148945', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148948', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148951', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148954', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148957', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148960', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148963', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148966', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148969', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148972', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148975', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148978', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148981', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148984', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148987', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148990', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148993', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148996', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1148999', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149002', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149005', 'drugName': 'Velcalcetide', 'tradeNames_list': "['Parsabiv']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.205 | Q16 | What Protein therapies have been approved by the FDA to treat lupus nephritis? | Voclosporin is the only Protein therapy approved by the FDA to treat lupus nephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lupus nephritis" OR LOWER(mesh_heading) = "lupus nephritis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192227', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000138814', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Nephritis', 'efo_term': 'lupus nephritis'}, {'UUID': 'DrugTargetsIndication121923_text_1192239', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000138814', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Nephritis', 'efo_term': 'lupus nephritis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1077 | Q16 | What Small molecule therapies have been approved by the FDA to treat fluoride poisoning? | There are no drug Small molecule therapies approved to treat fluoride poisoning. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fluoride poisoning" OR LOWER(mesh_heading) = "fluoride poisoning") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.53 | Q16 | What Protein therapies have been approved by the FDA to treat Merkel cell skin cancer? | There are no drug Protein therapies approved to treat Merkel cell skin cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "merkel cell skin cancer" OR LOWER(mesh_heading) = "merkel cell skin cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1313 | Q16 | What Small molecule therapies have been approved by the FDA to treat metabolic disease? | Alendronate Sodium is the only Small molecule therapy approved by the FDA to treat metabolic disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "metabolic disease" OR LOWER(mesh_heading) = "metabolic disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099489', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099496', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099503', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.549 | Q16 | What Small molecule therapies have been approved by the FDA to treat Miscarriage? | There are no drug Small molecule therapies approved to treat Miscarriage. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "miscarriage" OR LOWER(mesh_heading) = "miscarriage") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.69 | Q16 | What Protein therapies have been approved by the FDA to treat Thrombocytopenia? | Bivalirudin is the only Protein therapy approved by the FDA to treat Thrombocytopenia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombocytopenia" OR LOWER(mesh_heading) = "thrombocytopenia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092310', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1092327', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1092344', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1092361', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1262 | Q16 | What Small molecule therapies have been approved by the FDA to treat lung carcinoma? | There are no drug Small molecule therapies approved to treat lung carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lung carcinoma" OR LOWER(mesh_heading) = "lung carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.511 | Q16 | What Small molecule therapies have been approved by the FDA to treat IgG4-related retroperitoneal fibrosis? | There are no drug Small molecule therapies approved to treat IgG4-related retroperitoneal fibrosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "igg4-related retroperitoneal fibrosis" OR LOWER(mesh_heading) = "igg4-related retroperitoneal fibrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1363 | Q16 | What Small molecule therapies have been approved by the FDA to treat neoplasm of esophagus? | There are no drug Small molecule therapies approved to treat neoplasm of esophagus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neoplasm of esophagus" OR LOWER(mesh_heading) = "neoplasm of esophagus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.331 | Q16 | What Small molecule therapies have been approved by the FDA to treat Achalasia? | There are no drug Small molecule therapies approved to treat Achalasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "achalasia" OR LOWER(mesh_heading) = "achalasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1556 | Q16 | What Small molecule therapies have been approved by the FDA to treat pure red-cell aplasia? | There are no drug Small molecule therapies approved to treat pure red-cell aplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pure red-cell aplasia" OR LOWER(mesh_heading) = "pure red-cell aplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.184 | Q16 | What Protein therapies have been approved by the FDA to treat intermediate coronary syndrome? | Bivalirudin is the only Protein therapy approved by the FDA to treat intermediate coronary syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intermediate coronary syndrome" OR LOWER(mesh_heading) = "intermediate coronary syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092312', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1092329', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1092346', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_1092363', 'drugName': 'Bivalirudin', 'tradeNames_list': "['Angiomax', 'Angiomax rtu', 'BivalirudinBivalirudin in 0.9% sodium chloride']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000180210', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin', 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Unstable', 'efo_term': 'intermediate coronary syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.138 | Q16 | What Protein therapies have been approved by the FDA to treat coronary artery disease? | There are no drug Protein therapies approved to treat coronary artery disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "coronary artery disease" OR LOWER(mesh_heading) = "coronary artery disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.907 | Q16 | What Small molecule therapies have been approved by the FDA to treat choroideremia? | There are no drug Small molecule therapies approved to treat choroideremia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "choroideremia" OR LOWER(mesh_heading) = "choroideremia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.804 | Q16 | What Small molecule therapies have been approved by the FDA to treat autoimmune thrombocytopenia? | There are no drug Small molecule therapies approved to treat autoimmune thrombocytopenia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autoimmune thrombocytopenia" OR LOWER(mesh_heading) = "autoimmune thrombocytopenia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.133 | Q16 | What Protein therapies have been approved by the FDA to treat colorectal adenoma? | There are no drug Protein therapies approved to treat colorectal adenoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal adenoma" OR LOWER(mesh_heading) = "colorectal adenoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.81 | Q16 | What Protein therapies have been approved by the FDA to treat acute lung injury? | There are no drug Protein therapies approved to treat acute lung injury. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute lung injury" OR LOWER(mesh_heading) = "acute lung injury") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1418 | Q16 | What Small molecule therapies have been approved by the FDA to treat osteoarthritis, hip? | There are no drug Small molecule therapies approved to treat osteoarthritis, hip. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteoarthritis, hip" OR LOWER(mesh_heading) = "osteoarthritis, hip") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.106 | Q16 | What Protein therapies have been approved by the FDA to treat bone fracture? | There are no drug Protein therapies approved to treat bone fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone fracture" OR LOWER(mesh_heading) = "bone fracture") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1358 | Q16 | What Small molecule therapies have been approved by the FDA to treat myxoid liposarcoma? | There are no drug Small molecule therapies approved to treat myxoid liposarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myxoid liposarcoma" OR LOWER(mesh_heading) = "myxoid liposarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.545 | Q16 | What Small molecule therapies have been approved by the FDA to treat Meniere disease? | There are no drug Small molecule therapies approved to treat Meniere disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "meniere disease" OR LOWER(mesh_heading) = "meniere disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.998 | Q16 | What Small molecule therapies have been approved by the FDA to treat digestive system neoplasm? | There are no drug Small molecule therapies approved to treat digestive system neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "digestive system neoplasm" OR LOWER(mesh_heading) = "digestive system neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.484 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hepatopulmonary Syndrome? | There are no drug Small molecule therapies approved to treat Hepatopulmonary Syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hepatopulmonary syndrome" OR LOWER(mesh_heading) = "hepatopulmonary syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.166 | Q16 | What Protein therapies have been approved by the FDA to treat heart disease? | There are no drug Protein therapies approved to treat heart disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "heart disease" OR LOWER(mesh_heading) = "heart disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.250 | Q16 | What Protein therapies have been approved by the FDA to treat pain? | There are 2 Protein therapy drugs that are approved to treat pain which are as follows: Ziconotide Acetate and Ziconotide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pain" OR LOWER(mesh_heading) = "pain") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_891731', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891733', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891735', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891737', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891739', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891741', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891743', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891745', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891747', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891749', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891751', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891753', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891755', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891757', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891759', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891761', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891763', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891765', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891767', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_891769', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914651', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914653', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914655', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914657', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914659', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914661', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914663', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914665', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914667', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914669', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914671', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914673', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914675', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914677', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914679', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914681', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914683', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914685', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914687', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}, {'UUID': 'DrugTargetsIndication121923_text_914689', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'drugType': 'Protein', 'actionType': 'blocker', 'target': 'ENSG00000148408', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.309 | Q16 | What Protein therapies have been approved by the FDA to treat thyroid cancer? | There are no drug Protein therapies approved to treat thyroid cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thyroid cancer" OR LOWER(mesh_heading) = "thyroid cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.450 | Q16 | What Small molecule therapies have been approved by the FDA to treat Gaucher disease type 2? | There are no drug Small molecule therapies approved to treat Gaucher disease type 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gaucher disease type 2" OR LOWER(mesh_heading) = "gaucher disease type 2") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1009 | Q16 | What Small molecule therapies have been approved by the FDA to treat dyspepsia? | There are no drug Small molecule therapies approved to treat dyspepsia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dyspepsia" OR LOWER(mesh_heading) = "dyspepsia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.866 | Q16 | What Small molecule therapies have been approved by the FDA to treat cardiac arrest? | Epinephrine is the only Small molecule therapy approved by the FDA to treat cardiac arrest. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cardiac arrest" OR LOWER(mesh_heading) = "cardiac arrest") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360832', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_360885', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_360938', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_360991', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361044', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361097', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361150', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361203', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361256', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361309', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361362', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361415', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361468', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361521', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361574', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361627', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361680', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361733', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361786', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361839', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361892', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361945', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_361998', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362051', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362104', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362157', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362210', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362263', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362316', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362369', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362422', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362475', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362528', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362581', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362634', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362687', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362740', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362793', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362846', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362899', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_362952', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363005', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363058', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363111', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363164', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363217', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363270', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363323', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363376', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363429', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363482', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363535', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363588', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363641', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363694', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363747', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363800', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363853', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363906', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_363959', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364012', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364065', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364118', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364171', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364224', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364277', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364330', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364383', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364436', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364489', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364542', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364595', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364648', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364701', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364754', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364807', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364860', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364913', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_364966', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365019', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365072', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365125', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365178', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365231', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365284', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365337', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365390', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365443', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365496', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365549', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365602', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365655', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365708', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365761', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365814', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365867', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365920', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_365973', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_366026', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}, {'UUID': 'DrugTargetsIndication121923_text_366079', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.336 | Q16 | What Small molecule therapies have been approved by the FDA to treat Alagille syndrome? | Maralixibat Chloride is the only Small molecule therapy approved by the FDA to treat Alagille syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alagille syndrome" OR LOWER(mesh_heading) = "alagille syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_992697', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alagille Syndrome', 'efo_term': 'Alagille syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_992701', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alagille Syndrome', 'efo_term': 'Alagille syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_992705', 'drugName': 'Maralixibat Chloride', 'tradeNames_list': "['Livmarli']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000125255', 'approvedSymbol': 'SLC10A2', 'approvedName': 'solute carrier family 10 member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alagille Syndrome', 'efo_term': 'Alagille syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1166 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypertrophy? | There are no drug Small molecule therapies approved to treat hypertrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypertrophy" OR LOWER(mesh_heading) = "hypertrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.857 | Q16 | What Small molecule therapies have been approved by the FDA to treat burn? | Lidocaine is the only Small molecule therapy approved by the FDA to treat burn. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "burn" OR LOWER(mesh_heading) = "burn") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637790', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_637905', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638020', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638135', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638250', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638365', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638480', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638595', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638710', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638825', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_638940', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639055', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639170', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639285', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639400', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639515', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639630', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639745', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639860', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_639975', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640090', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640205', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640320', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640435', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640550', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640665', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640780', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_640895', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641010', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641125', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641240', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641355', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641470', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641585', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641700', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641815', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_641930', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642045', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642160', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642275', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642390', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642505', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642620', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642735', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642850', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_642965', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643080', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643195', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643310', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643425', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643540', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643655', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643770', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_643885', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_644000', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_644115', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_644230', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_644345', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_644460', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}, {'UUID': 'DrugTargetsIndication121923_text_644575', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Burns', 'efo_term': 'burn'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.98 | Q16 | What Protein therapies have been approved by the FDA to treat atrioventricular septal defect? | There are no drug Protein therapies approved to treat atrioventricular septal defect. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atrioventricular septal defect" OR LOWER(mesh_heading) = "atrioventricular septal defect") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1030 | Q16 | What Small molecule therapies have been approved by the FDA to treat ependymoma? | There are no drug Small molecule therapies approved to treat ependymoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ependymoma" OR LOWER(mesh_heading) = "ependymoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1737 | Q16 | What Small molecule therapies have been approved by the FDA to treat uterine fibroid? | There are no drug Small molecule therapies approved to treat uterine fibroid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "uterine fibroid" OR LOWER(mesh_heading) = "uterine fibroid") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.743 | Q16 | What Small molecule therapies have been approved by the FDA to treat alternating hemiplegia of childhood? | There are no drug Small molecule therapies approved to treat alternating hemiplegia of childhood. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alternating hemiplegia of childhood" OR LOWER(mesh_heading) = "alternating hemiplegia of childhood") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1111 | Q16 | What Small molecule therapies have been approved by the FDA to treat glioma? | There are no drug Small molecule therapies approved to treat glioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "glioma" OR LOWER(mesh_heading) = "glioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1280 | Q16 | What Small molecule therapies have been approved by the FDA to treat malaria? | Doxycycline is the only Small molecule therapy approved by the FDA to treat malaria. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malaria" OR LOWER(mesh_heading) = "malaria") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1037845', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1037920', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1037995', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038070', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038145', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038220', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038295', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038370', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038445', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038520', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038595', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038670', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038745', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038820', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038895', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1038970', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039045', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039120', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039195', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039270', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039345', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039420', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039495', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039570', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039645', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039720', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039795', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039870', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1039945', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040020', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040095', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040170', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040245', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040320', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040395', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040470', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040545', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040620', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040695', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040770', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040845', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040920', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1040995', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}, {'UUID': 'DrugTargetsIndication121923_text_1041070', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.425 | Q16 | What Small molecule therapies have been approved by the FDA to treat End Stage Liver Disease? | There are no drug Small molecule therapies approved to treat End Stage Liver Disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "end stage liver disease" OR LOWER(mesh_heading) = "end stage liver disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.103 | Q16 | What Protein therapies have been approved by the FDA to treat benign prostatic hyperplasia? | There are no drug Protein therapies approved to treat benign prostatic hyperplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "benign prostatic hyperplasia" OR LOWER(mesh_heading) = "benign prostatic hyperplasia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.438 | Q16 | What Small molecule therapies have been approved by the FDA to treat Fallopian Tube Carcinoma? | Niraparib Tosylate is the only Small molecule therapy approved by the FDA to treat Fallopian Tube Carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fallopian tube carcinoma" OR LOWER(mesh_heading) = "fallopian tube carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823335', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823339', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823343', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823347', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823351', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823355', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823359', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823363', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823367', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823371', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823375', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_823379', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143799', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.75 | Q16 | What Protein therapies have been approved by the FDA to treat achondroplasia? | Vosoritide is the only Protein therapy approved by the FDA to treat achondroplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "achondroplasia" OR LOWER(mesh_heading) = "achondroplasia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192659', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192661', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192662', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192664', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192665', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192667', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192668', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192670', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192671', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192673', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192674', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192676', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192677', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192679', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192680', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192682', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192683', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192685', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192686', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192688', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192689', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192691', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}, {'UUID': 'DrugTargetsIndication121923_text_1192692', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': None}, {'UUID': 'DrugTargetsIndication121923_text_1192694', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Achondroplasia', 'efo_term': 'achondroplasia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1577 | Q16 | What Small molecule therapies have been approved by the FDA to treat respiratory tract infectious disorder? | There are no drug Small molecule therapies approved to treat respiratory tract infectious disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory tract infectious disorder" OR LOWER(mesh_heading) = "respiratory tract infectious disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.917 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic kidney disease? | There are 3 Small molecule therapy drugs that are approved to treat chronic kidney disease which are as follows: Calcifediol, Finerenone, and Cinacalcet Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic kidney disease" OR LOWER(mesh_heading) = "chronic kidney disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823386', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823394', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823402', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823410', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823418', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823426', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823434', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823442', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823450', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823458', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823466', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823474', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823482', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823490', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823498', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823506', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823514', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823522', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_823530', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000111424', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1094663', 'drugName': 'Finerenone', 'tradeNames_list': "['Kerendia']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1094667', 'drugName': 'Finerenone', 'tradeNames_list': "['Kerendia']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149010', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149015', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149020', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149025', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149030', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}, {'UUID': 'DrugTargetsIndication121923_text_1149035', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000036828', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1066 | Q16 | What Small molecule therapies have been approved by the FDA to treat female reproductive system neoplasm? | There are no drug Small molecule therapies approved to treat female reproductive system neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "female reproductive system neoplasm" OR LOWER(mesh_heading) = "female reproductive system neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.230 | Q16 | What Protein therapies have been approved by the FDA to treat myocarditis? | There are no drug Protein therapies approved to treat myocarditis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myocarditis" OR LOWER(mesh_heading) = "myocarditis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1681 | Q16 | What Small molecule therapies have been approved by the FDA to treat tachypnea? | There are no drug Small molecule therapies approved to treat tachypnea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tachypnea" OR LOWER(mesh_heading) = "tachypnea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.926 | Q16 | What Small molecule therapies have been approved by the FDA to treat cicatricial alopecia? | There are no drug Small molecule therapies approved to treat cicatricial alopecia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cicatricial alopecia" OR LOWER(mesh_heading) = "cicatricial alopecia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.304 | Q16 | What Protein therapies have been approved by the FDA to treat systemic lupus erythematosus? | There are no drug Protein therapies approved to treat systemic lupus erythematosus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "systemic lupus erythematosus" OR LOWER(mesh_heading) = "systemic lupus erythematosus") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1511 | Q16 | What Small molecule therapies have been approved by the FDA to treat postpoliomyelitis syndrome? | There are no drug Small molecule therapies approved to treat postpoliomyelitis syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "postpoliomyelitis syndrome" OR LOWER(mesh_heading) = "postpoliomyelitis syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1516 | Q16 | What Small molecule therapies have been approved by the FDA to treat pregnancy? | There are no drug Small molecule therapies approved to treat pregnancy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pregnancy" OR LOWER(mesh_heading) = "pregnancy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1431 | Q16 | What Small molecule therapies have been approved by the FDA to treat ovarian neoplasm? | There are 2 Small molecule therapy drugs that are approved to treat ovarian neoplasm which are as follows: Olaparib and Topotecan Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ovarian neoplasm" OR LOWER(mesh_heading) = "ovarian neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_795057', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795124', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795191', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795258', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795325', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795392', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795459', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795526', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795593', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795660', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795727', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795794', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795861', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795928', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_795995', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796062', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796129', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796196', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796263', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796330', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796397', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796464', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796531', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796598', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796665', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796732', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796799', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796866', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_796933', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797000', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797067', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797134', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797201', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797268', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797335', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797402', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797469', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797536', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797603', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797670', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797737', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797804', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797871', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_797938', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798005', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798072', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798139', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798206', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798273', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798340', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798407', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798474', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798541', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798608', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798675', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798742', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798809', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798876', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_798943', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799010', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799077', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799144', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799211', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799278', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799345', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799412', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799479', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799546', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799613', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799680', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799747', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799814', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799881', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_799948', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800015', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800082', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800149', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800216', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800283', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800350', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800417', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800484', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800551', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800618', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800685', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800752', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800819', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800886', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_800953', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801020', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801087', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801154', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801221', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801288', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801355', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801422', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801489', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801556', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801623', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_801690', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000129484', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.832 | Q16 | What Small molecule therapies have been approved by the FDA to treat bone metastasis? | Zoledronic Acid is the only Small molecule therapy approved by the FDA to treat bone metastasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone metastasis" OR LOWER(mesh_heading) = "bone metastasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099607', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099662', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099717', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099772', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099827', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099882', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099937', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1099992', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1100047', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1100102', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1100157', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}, {'UUID': 'DrugTargetsIndication121923_text_1100212', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'bone metastasis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.770 | Q16 | What Small molecule therapies have been approved by the FDA to treat anogenital venereal wart? | There are no drug Small molecule therapies approved to treat anogenital venereal wart. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anogenital venereal wart" OR LOWER(mesh_heading) = "anogenital venereal wart") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.739 | Q16 | What Small molecule therapies have been approved by the FDA to treat allergic contact dermatitis? | There are no drug Small molecule therapies approved to treat allergic contact dermatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "allergic contact dermatitis" OR LOWER(mesh_heading) = "allergic contact dermatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.997 | Q16 | What Small molecule therapies have been approved by the FDA to treat digestive system disease? | Lidocaine is the only Small molecule therapy approved by the FDA to treat digestive system disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "digestive system disease" OR LOWER(mesh_heading) = "digestive system disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637781', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_637896', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638011', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638126', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638241', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638356', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638471', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638586', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638701', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638816', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_638931', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639046', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639161', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639276', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639391', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639506', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639621', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639736', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639851', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_639966', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640081', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640196', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640311', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640426', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640541', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640656', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640771', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_640886', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641001', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641116', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641231', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641346', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641461', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641576', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641691', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641806', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_641921', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642036', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642151', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642266', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642381', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642496', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642611', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642726', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642841', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_642956', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643071', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643186', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643301', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643416', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643531', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643646', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643761', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643876', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_643991', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_644106', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_644221', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_644336', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_644451', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}, {'UUID': 'DrugTargetsIndication121923_text_644566', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rectal Diseases', 'efo_term': 'digestive system disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.391 | Q16 | What Small molecule therapies have been approved by the FDA to treat Chronic pain? | There are 9 Small molecule therapy drugs that are approved to treat Chronic pain which are as follows: Duloxetine Hydrochloride, Tapentadol Hydrochloride, Morphine Sulfate, Buprenorphine, Tramadol Hydrochloride, Oxycodone Hydrochloride, Oxycodone, Fentanyl, and Lubiprostone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic pain" OR LOWER(mesh_heading) = "chronic pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205994', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206010', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206026', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206042', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206058', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206074', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206090', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206106', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206122', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206138', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206154', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206170', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206186', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206202', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206218', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206234', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206250', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206266', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206282', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206298', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206314', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206330', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206346', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206362', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206378', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206394', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206410', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206426', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206442', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206458', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206474', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206490', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434244', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434249', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434254', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434259', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434264', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434269', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434274', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434279', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434284', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434289', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434294', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434299', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434304', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434309', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434314', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434319', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434324', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434329', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434334', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434339', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434344', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434349', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434354', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434359', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434364', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434369', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434374', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434379', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434384', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434389', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434394', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434399', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434404', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434409', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434414', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434419', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434424', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434429', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434434', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434439', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434444', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434449', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434454', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434459', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434464', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434469', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434474', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434479', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434484', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434489', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434494', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434499', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434504', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434509', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434514', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434519', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434524', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434529', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434534', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434539', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434544', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434549', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434554', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434559', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434564', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434569', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434574', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434579', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.237 | Q16 | What Protein therapies have been approved by the FDA to treat neuroepithelial neoplasm? | There are no drug Protein therapies approved to treat neuroepithelial neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroepithelial neoplasm" OR LOWER(mesh_heading) = "neuroepithelial neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1456 | Q16 | What Small molecule therapies have been approved by the FDA to treat penile neoplasm? | There are no drug Small molecule therapies approved to treat penile neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "penile neoplasm" OR LOWER(mesh_heading) = "penile neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1617 | Q16 | What Small molecule therapies have been approved by the FDA to treat severe acute respiratory syndrome? | There are no drug Small molecule therapies approved to treat severe acute respiratory syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "severe acute respiratory syndrome" OR LOWER(mesh_heading) = "severe acute respiratory syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.269 | Q16 | What Protein therapies have been approved by the FDA to treat primary membranoproliferative glomerulonephritis? | There are no drug Protein therapies approved to treat primary membranoproliferative glomerulonephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary membranoproliferative glomerulonephritis" OR LOWER(mesh_heading) = "primary membranoproliferative glomerulonephritis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.307 | Q16 | What Protein therapies have been approved by the FDA to treat thrombotic thrombocytopenic purpura? | There are no drug Protein therapies approved to treat thrombotic thrombocytopenic purpura. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombotic thrombocytopenic purpura" OR LOWER(mesh_heading) = "thrombotic thrombocytopenic purpura") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1170 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypopharyngeal carcinoma? | There are no drug Small molecule therapies approved to treat hypopharyngeal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypopharyngeal carcinoma" OR LOWER(mesh_heading) = "hypopharyngeal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1756 | Q16 | What Small molecule therapies have been approved by the FDA to treat vitamin D deficiency? | There are no drug Small molecule therapies approved to treat vitamin D deficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vitamin d deficiency" OR LOWER(mesh_heading) = "vitamin d deficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.118 | Q16 | What Protein therapies have been approved by the FDA to treat carcinoma? | Goserelin Acetate is the only Protein therapy approved by the FDA to treat carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carcinoma" OR LOWER(mesh_heading) = "carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096828', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1096842', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1096856', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_1096870', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1417 | Q16 | What Small molecule therapies have been approved by the FDA to treat osteitis deformans? | There are 2 Small molecule therapy drugs that are approved to treat osteitis deformans which are as follows: Alendronate Sodium and Zoledronic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "osteitis deformans" OR LOWER(mesh_heading) = "osteitis deformans") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099428', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099435', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099442', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099449', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099456', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099463', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099470', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099492', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099499', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099506', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099605', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099609', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099660', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099664', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099715', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099719', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099770', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099774', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099825', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099829', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099880', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099884', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099935', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099939', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1099990', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1099994', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100045', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1100049', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100100', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1100104', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100155', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1100159', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100210', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'osteitis deformans'}, {'UUID': 'DrugTargetsIndication121923_text_1100214', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160752', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteitis Deformans', 'efo_term': 'Paget disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.677 | Q16 | What Small molecule therapies have been approved by the FDA to treat Vitiligo? | There are no drug Small molecule therapies approved to treat Vitiligo. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vitiligo" OR LOWER(mesh_heading) = "vitiligo") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.251 | Q16 | What Protein therapies have been approved by the FDA to treat pancreatic carcinoma? | There are no drug Protein therapies approved to treat pancreatic carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pancreatic carcinoma" OR LOWER(mesh_heading) = "pancreatic carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1592 | Q16 | What Small molecule therapies have been approved by the FDA to treat rosacea? | There are 3 Small molecule therapy drugs that are approved to treat rosacea which are as follows: Oxymetazoline Hydrochloride, Brimonidine Tartrate, and Doxycycline. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rosacea" OR LOWER(mesh_heading) = "rosacea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_417194', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417204', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417214', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417224', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417234', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417244', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417254', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417264', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417274', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417284', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417294', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417304', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417314', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417324', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417334', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417344', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417354', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417364', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417374', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417384', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417394', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417404', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417414', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417424', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417434', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417444', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417454', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417464', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417474', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417484', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417494', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417504', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417514', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417524', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417534', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417544', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417554', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417564', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417574', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417584', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417594', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417604', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417614', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417624', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417634', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417644', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417654', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417664', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417674', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417684', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417694', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000170214', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417704', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417714', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417724', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417734', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417744', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417754', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417764', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417774', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417784', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417794', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417804', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417814', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417824', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417834', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417844', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417854', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417864', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417874', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417884', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417894', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417904', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417914', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417924', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417934', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417944', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417954', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417964', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417974', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417984', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_417994', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418004', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418014', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418024', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418034', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418044', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418054', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418064', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418074', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418084', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418094', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418104', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418114', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418124', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418134', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418144', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418154', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418164', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418174', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}, {'UUID': 'DrugTargetsIndication121923_text_418184', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.95 | Q16 | What Protein therapies have been approved by the FDA to treat aspergillosis? | There are no drug Protein therapies approved to treat aspergillosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "aspergillosis" OR LOWER(mesh_heading) = "aspergillosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.34 | Q16 | What Protein therapies have been approved by the FDA to treat Constipation? | There are 2 Protein therapy drugs that are approved to treat Constipation which are as follows: Linaclotide and Plecanatide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "constipation" OR LOWER(mesh_heading) = "constipation") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092087', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092089', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092091', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092093', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092095', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092097', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092099', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092101', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092103', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092105', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092107', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092109', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092111', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092113', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092115', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092117', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092119', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092121', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092123', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092125', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092127', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092129', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092131', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092133', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092135', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092137', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092139', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092141', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092143', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092145', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092147', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092149', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092151', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092153', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092155', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092157', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092159', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092161', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092163', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092165', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092167', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092169', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092171', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092173', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092175', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092177', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092179', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092181', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092183', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092185', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092187', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092189', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092191', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092193', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092195', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092197', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092199', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092201', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092203', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092205', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092207', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092209', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092211', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092213', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092215', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092217', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092219', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092221', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092223', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092225', 'drugName': 'Linaclotide', 'tradeNames_list': "['Constella', 'Linzess']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1092227', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092229', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092231', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092233', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092235', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092237', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092239', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092241', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092243', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092245', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092247', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1092249', 'drugName': 'Plecanatide', 'tradeNames_list': "['Trulance']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000070019', 'approvedSymbol': 'GUCY2C', 'approvedName': 'guanylate cyclase 2C', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1284 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant epithelial tumor of ovary? | Topotecan Hydrochloride is the only Small molecule therapy approved by the FDA to treat malignant epithelial tumor of ovary. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant epithelial tumor of ovary" OR LOWER(mesh_heading) = "malignant epithelial tumor of ovary") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193579', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'malignant epithelial tumor of ovary'}, {'UUID': 'DrugTargetsIndication121923_text_1193651', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'malignant epithelial tumor of ovary'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1473 | Q16 | What Small molecule therapies have been approved by the FDA to treat pharyngitis? | There are 2 Small molecule therapy drugs that are approved to treat pharyngitis which are as follows: Acetaminophen and Ibuprofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pharyngitis" OR LOWER(mesh_heading) = "pharyngitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828742', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_828847', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_828952', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829057', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829162', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829267', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829372', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829477', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829582', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829687', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829792', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_829897', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830002', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830107', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830212', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830317', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830422', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830527', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830632', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830737', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830842', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_830947', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831052', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831157', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831262', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831367', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831472', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831577', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831682', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831787', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831892', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_831997', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832102', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832207', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832312', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832417', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832522', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832627', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832732', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_832837', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_839778', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_839857', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_839936', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840015', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840094', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840173', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840252', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840331', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840410', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840489', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840568', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840647', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840726', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840805', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840884', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_840963', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841042', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841121', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841200', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841279', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841358', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841437', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841516', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841595', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841674', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}, {'UUID': 'DrugTargetsIndication121923_text_841753', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pharyngitis', 'efo_term': 'pharyngitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.452 | Q16 | What Small molecule therapies have been approved by the FDA to treat Generalized non-motor (absence) seizure? | There are no drug Small molecule therapies approved to treat Generalized non-motor (absence) seizure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "generalized non-motor (absence) seizure" OR LOWER(mesh_heading) = "generalized non-motor (absence) seizure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.722 | Q16 | What Small molecule therapies have been approved by the FDA to treat adult T-cell leukemia/lymphoma? | There are no drug Small molecule therapies approved to treat adult T-cell leukemia/lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adult t-cell leukemia/lymphoma" OR LOWER(mesh_heading) = "adult t-cell leukemia/lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1272 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphoid neoplasm? | There are no drug Small molecule therapies approved to treat lymphoid neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoid neoplasm" OR LOWER(mesh_heading) = "lymphoid neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1337 | Q16 | What Small molecule therapies have been approved by the FDA to treat mucositis? | There are no drug Small molecule therapies approved to treat mucositis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mucositis" OR LOWER(mesh_heading) = "mucositis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat Acute hepatic porphyria? | Givosiran Sodium is the only Oligonucleotide therapy approved by the FDA to treat Acute hepatic porphyria. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute hepatic porphyria" OR LOWER(mesh_heading) = "acute hepatic porphyria") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100360', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100362', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100364', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100366', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100368', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100370', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100372', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100374', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100376', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100378', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100380', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100382', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}, {'UUID': 'DrugTargetsIndication121923_text_1100384', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1206 | Q16 | What Small molecule therapies have been approved by the FDA to treat interstitial cystitis? | There are no drug Small molecule therapies approved to treat interstitial cystitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "interstitial cystitis" OR LOWER(mesh_heading) = "interstitial cystitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.83 | Q16 | What Protein therapies have been approved by the FDA to treat acute myeloid leukemia? | There are no drug Protein therapies approved to treat acute myeloid leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute myeloid leukemia" OR LOWER(mesh_heading) = "acute myeloid leukemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1537 | Q16 | What Small molecule therapies have been approved by the FDA to treat prostate adenocarcinoma? | There are 7 Small molecule therapy drugs that are approved to treat prostate adenocarcinoma which are as follows: Cabazitaxel, Enzalutamide, Apalutamide, Darolutamide, Abiraterone Acetate, Relugolix, and Zoledronic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate adenocarcinoma" OR LOWER(mesh_heading) = "prostate adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_67882', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67906', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67930', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67954', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67978', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68002', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68026', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68050', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68074', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68098', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68122', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68146', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68170', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68194', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68218', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68242', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68266', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68290', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68314', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68338', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68362', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68386', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68410', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68434', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68458', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68482', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68506', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68530', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68554', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68578', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68602', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68626', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68650', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68674', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68698', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68722', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68746', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68770', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68794', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68818', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68842', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68866', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68890', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68914', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68938', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68962', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68986', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69010', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69034', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69058', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69082', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69106', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69130', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69154', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69178', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69202', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69226', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69250', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69274', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69298', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69322', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69346', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69370', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69394', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69418', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69442', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69466', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69490', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69514', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69538', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69562', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69586', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69610', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69634', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69658', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69682', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69706', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69730', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69754', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69778', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69802', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69826', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69850', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69874', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69898', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69922', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69946', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69970', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69994', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_70018', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921031', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921050', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921069', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921088', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921107', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921126', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921145', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921164', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921183', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_921202', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.681 | Q16 | What Small molecule therapies have been approved by the FDA to treat Waldenstrom macroglobulinemia? | Ibrutinib is the only Small molecule therapy approved by the FDA to treat Waldenstrom macroglobulinemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "waldenstrom macroglobulinemia" OR LOWER(mesh_heading) = "waldenstrom macroglobulinemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_995035', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995036', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995081', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995082', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995127', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995128', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995173', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995174', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995219', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995220', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995265', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995266', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995311', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995312', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995357', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995358', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995403', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995404', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995449', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995450', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995495', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995496', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995541', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995542', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995587', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995588', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995633', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995634', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995679', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995680', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995725', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995726', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995771', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995772', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995817', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995818', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995863', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995864', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995909', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995910', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995955', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_995956', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996001', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996002', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996047', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996048', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996093', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996094', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996139', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996140', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996185', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996186', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996231', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996232', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996277', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996278', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996323', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996324', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996369', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996370', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996415', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996416', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996461', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996462', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996507', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996508', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996553', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996554', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996599', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996600', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996645', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996646', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996691', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996692', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996737', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996738', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996783', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996784', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996829', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996830', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996875', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996876', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996921', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996922', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996967', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_996968', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997013', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997014', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997059', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997060', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997105', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997106', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997151', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997152', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997197', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997198', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997243', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997244', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997289', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'macroglobulinemia'}, {'UUID': 'DrugTargetsIndication121923_text_997290', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Waldenstrom Macroglobulinemia', 'efo_term': 'Waldenstrom macroglobulinemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1273 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphoma? | There are 4 Small molecule therapy drugs that are approved to treat lymphoma which are as follows: Prednisone, Dexamethasone, Duvelisib, and Lorlatinib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoma" OR LOWER(mesh_heading) = "lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217632', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_217840', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_218048', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_218256', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_218464', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_218672', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_218880', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_219088', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_219296', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_219504', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_219712', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_219920', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_220128', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_220336', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_220544', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_220752', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_226325', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_226610', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_226895', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_227180', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_227465', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_227750', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_228035', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_228320', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_228605', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_228890', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_229175', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_229460', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_229745', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_230030', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_230315', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_230600', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_230885', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_231170', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_231455', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_231740', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_232025', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_232310', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858738', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858758', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858778', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858798', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858818', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858838', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858858', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858878', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858898', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858918', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858938', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858958', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858978', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_858998', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859018', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859038', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859058', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859078', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859098', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859118', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859138', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859158', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859178', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859198', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859218', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859238', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859258', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_859278', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991029', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991037', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991045', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991053', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991061', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991069', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991077', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991085', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991093', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991101', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991109', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991117', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991125', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991133', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991141', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991149', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991157', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991165', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991173', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991181', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171094', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991189', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991197', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991205', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991213', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991221', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991229', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991237', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991245', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991253', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_991261', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000143924', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma', 'efo_term': 'lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.